RenewMD and Dr
Special considerations for specific populations Switching with type 2 diabetes If you are using semaglutide for both diabetes management and weight loss, the switch to tirzepatide requires extra monitoring
In the meantime, Mounjaro at 22.5% average weight loss remains the strongest licensed option available and produces results that, until recently, would also have seemed impossible. TRIUMPH-1 Extension: Results to 104 Weeks A pre-specified blinded extension of TRIUMPH-1 followed 532 participants with a baseline BMI of 35 or higher who completed the main 80-week study
Diabetes Ther 14(4):777786 Ceasovschih A, Asaftei A, Lupo MG, Kotlyarov S, Bartuskova H, Balta A et al (2025) Glucagon-like peptide-1 receptor agonists and muscle mass effects
It addresses all three failure points: dormant follicles, damaged tissue, and poor absorption